The AI in Clinical Trials Market enables pharmaceutical companies and contract research organizations (CROs) to leverage artificial intelligence tools across various stages of the clinical trial process. AI tools help in tasks like patient recruitment and retention, protocol design, site selection, monitoring, and analytics. It also enables precision diagnosis of diseases by studying huge volumes of medical images and genetic data. AI has the potential to expedite clinical trials by reducing trial duration by analyzing complex datasets. With AI powering clinical decisions, clinical study design becomes more targeted and adaptive.
The AI In Clinical Trials Market is estimated to be valued at US$ 1.42 Bn in 2024 and is expected to exhibit a CAGR of 29% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the AI in Clinical Trials are Aegle Therapeutics, Coya Therapeutics, Evox Therapeutics, Nano 24, ReNeuron. These companies are investing heavily in development of AI platforms and tools that can accelerate clinical trials.
Growing research in areas of precision medicine and drug discovery has increased the generation of large patient datasets comprising of genetic profiles, medical images and electronic health records. AI tools are able to analyze these diverse data types and extract meaningful insights for clinical trial design and targeted patient recruitment.
Latest technologies like machine learning and deep learning have enabled real-time analysis of huge volumes of unstructured medical data. AI is now powering clinical decisions by identifying disease subtypes, predicting drug responses and monitoring patients continuously during trials through wearable devices and mobile apps.
Market Trends
Increased adoption of decentralized or virtual clinical trials: The COVID-19 pandemic accelerated the need for adopting alternative clinical trial models like virtual/decentralized trials. AI tools enabled remote patient monitoring and digital endpoints which are key enablers for virtual trials.
Personalized medicine is driving targeting patient recruitment: AI algorithms analyzing multi-omics datasets are helping pharmaceutical firms design more targeted trials by better patient stratification. It is reducing screening failure rates through precision recruitment.
Market Opportunities
AI solutions for site feasibility and patient identification hold strong growth potential. Developing AI platforms for monitoring clinical trials more closely and detecting any deviations or violations in protocol will help improve compliance. There is also scope for using AI and machine learning tools to speed up clinical trial data analysis and generation of insights.
Impact Of COVID-19 On AI In Clinical Trials Market Growth:
The COVID-19 pandemic has significantly impacted the growth of the AI in clinical trials market. Due to various restrictions imposed during the pandemic such as lockdowns and social distancing norms, clinical trials faced many challenges in operations. Several clinical trials were delayed or postponed during this period. However, AI technologies played a crucial role in overcoming some of these challenges. With work from home becoming the new norm, AI tools enabled decentralized clinical trials with remote patient monitoring and virtual or teleclinical trials. This boosted the use of AI in clinical research during COVID-19. AI-powered solutions helped in areas such as patient recruitment, drug discovery and development, and predictive analysis of disease progression. In the post-COVID scenario, adoption of advanced digital technologies such as AI and machine learning in clinical research is expected to further accelerate. Hybrid models combining in-person and virtual clinical trial methodologies are expected to become more popular.
Geographical Regions With Highest Value Concentration In AI In Clinical Trials Market:
North America accounts for the highest value share in the global AI in clinical trials market. This can be attributed to factors such as strong presence of leading pharmaceutical companies and clinical research organizations in countries like the US and growing investments in AI and healthcare technologies. The US government is also undertaking various initiatives such as 21st Century Cures Act to support innovation and advancement of digital health technologies including AI. These developments are fueling the adoption of AI-powered clinical trial solutions in North America. Europe is another major regional market owing to increasing healthcare expenditures and rising emphasis on personalized medicine research in countries like Germany, UK and France.
Fastest Growing Regional Market:
The Asia Pacific region is poised to witness the fastest growth in the AI in clinical trials market during the forecast period. This is due to improving healthcare infrastructure, expanding patient pool, and rising investment activities of pharmaceutical companies in emerging countries of China and India. Favorable government policies supporting digital transformation of the healthcare sector also contribute to market growth. Initiatives like Digital India and Made in China 2025 present lucrative opportunities for AI companies to develop novel clinical trial tools customized for the Asia Pacific population. Overall, increasing R&D spending on pharmaceuticals and focus on precision medicine is fueling the integration of AI technologies across clinical research pipelines in Asia Pacific.
Get more insights on this topic: https://www.pressreleasebulletin.com/ai-in-clinical-trials-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-deep-learning-techniques/
Author Bio:
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. (LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
What Are The Key Data Covered In This AI In Clinical Trials Market Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the AI In Clinical Trials Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the AI In Clinical Trials Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- AI In Clinical Trials Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of AI In Clinical Trials Market vendors
FAQ’s
Q.1 What are the main factors influencing the AI In Clinical Trials Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top AI In Clinical Trials Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the AI In Clinical Trials Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment